Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis ClinicalTrials.gov, 5 Dec 2012 Accessed on 16 Sep 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01191996.
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis ClinicalTrials.gov, 26 Aug 2014 Accessed on 16 Sep 2014 from http://www.clinicaltrials.gov/ct2/show/NCT02228213.
MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA Vaccine. 2011 Jan 10; 29(3):545-57. Epub 2010 Oct 27. PMID: 21034827. Abstract
Microparticle Platform Innate Immunotherapeutics, 2014 Accessed on 19 Sep 2014 from http://www.innateimmunotherapeutics.com/irm/content/microparticle-platform.aspx?RID=308.
Lead Candidate (MIS416) Overview Innate Immunotherapeutics, 2014 Accessed on 19 Sep 2014 from http://www.innateimmunotherapeutics.com/irm/content/overview.aspx?RID=306.
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. White M, Webster G, O'Sullivan D, Stone S, La Flamme A C PLoS One. 2014; 9(1):e87712. Epub 2014 Jan 31. PMID: 24498172. Abstract
Compassionate Use Programme Update Innate Immunotherapeutics, 18 Jun 2014 Accessed on 30 Sep 2014 from http://www.innateimmuno.com/IRM/Company/ShowPage.aspx/PDFs/1027-10000000/CompassionateUseProgrammeUpdate.
New Microparticle Secondary Progressive MS Therapy Dosing Tested In Australian Clinical Trial Moore C, Multiple Sclerosis News Today, 13 Nov 2014 Accessed on 18 Nov 2014 from http://multiplesclerosisnewstoday.com/2014/11/13/new-microparticle-secondary-progressive-ms-therapy-dosing-tested-in-australian-clinical-trial/.
Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners Innate Immunotherapeutics, 13 Apr 2016 Accessed on 19 Apr 2016 from http://www.innateimmuno.com/IRM/PDF/1219/ClinicalTrialFullyEnrolledandStrongInterest.